Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can fixing your sleep schedule prevent diabetes? new study investigates

NCT ID NCT07494084

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

This study looks at how losing sleep and having a disrupted body clock (like shift workers) can make the body less responsive to insulin, a key step toward obesity and type 2 diabetes. Researchers will test 48 healthy adults aged 18-45 to see how the timing of the stress hormone cortisol affects insulin resistance. The goal is to better understand these links and find ways to help people avoid the negative health effects of chronic sleep loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Must be between 18-45 years old. 2. Has a BMI of 18-25 kg/m2 stable weight over the previous 6 weeks. 3. Is physically and psychologically healthy (incl. regular menstrual cycles in women, no clinical disorders and/or illnesses). Women will be studied during the follicular phase of their menstrual cycle. Menstrual cycle criteria (using PMID 10941950) 18 to 25 years - Cycle variation ≤9 days 26 to 41 years - Cycle variation ≤7 days 42 to 45 years - Cycle variation ≤9 days 4. No current medical or drug treatment (to include steroids or hormones of any type including contraceptives), as assessed by questionnaire. 5. Has a negative pregnancy test (women), no clinically significant abnormalities in blood and urine, and free of traces of drugs. 6. No history of clinically relevant psychiatric illness. 7. No previous history of drug or alcohol abuse. 8. Not a current smoker. 9. No history of brain injury or of learning disability. 10. No previous adverse reaction to sleep deprivation, jet lag, shift work or any of the drugs to be administered. 11. Not vision or hearing impairment unless corrected back to normal. 12. No endocrine disorder (no abnormal thyroid function tests; no abnormal morning blood cortisol; no primary gonadal disease as indicated by serum LH or FSH concentration \> 10 or \> 15 IU/L, respectively; and no hyperprolactinemia indicated by prolactin \> 25 μg/L). 13. No sleep or circadian disorder. 14. Has good habitual sleep with regular bedtimes (between 6 and 10 hours in duration). 15. Not extreme morning- nor extreme evening-type using Horne-Ostberg Morningness-Eveningness criteria. 16. No travel across time zones within one month of entering the study. 17. No shift work within three months of entering the study. 18. No anemia (hematocrit \<38% in men, \<34% in women). 19. No blood donation within the previous 8 weeks. 20. No concurrent participation in another research study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Circadian misalignment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sleep and Performance Research Center

    RECRUITING

    Spokane, Washington, 99202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.